Biotechnology

KalVista Pharma

Chiesi to Acquire KalVista Pharmaceuticals for $1.9 Billion in Cash

HC Wainwright Upgrades KalVista Pharmaceuticals Stock Rating

Stifel Nicolaus Analyst Maintains Buy Rating on KalVista Pharmaceuticals

KalVista Pharmaceuticals Reports Q4 Revenue, Shares Up 14%

KalVista Pharmaceuticals reports Q4 2025 net product revenue of about $35 million, plans Latin America commercialization

KalVista Pharma to release FY2025 Q3 earnings on November 11 Pre-Market EST, forecast revenue USD 4.2 M, EPS USD -1.02

KalVista Pharmaceuticals Proposes $110 Million Convertible Senior Notes Offering

KalVista to Present New Data on EKTERLY for HAE at German Allergy Congress

KalVista Pharmaceuticals Announces $110 Million Convertible Debt Offering, Shares Drop 10.3%

KalVista Pharmaceuticals Obtains EU and Swiss Approval for EKTERLY® and Plans for Market Launch

KalVista Pharma released FY2026 Q1 earnings on September 11 Pre-Market (EST), actual revenue USD 40.86 M (forecast USD 39.14 M), actual EPS USD -0.4302 (forecast USD -0.3762)

KalVista Pharmaceuticals to Release Q1 Earnings and Make Regulatory Progress on EKTERLY

KalVista Pharma to Release FY2026 Q1 Earnings on September 11, Pre-Market EST; Forecast Revenue USD 2.089 M, EPS USD -0.955

KalVista Pharmaceuticals Executives Sell Stocks to Pay Tax Obligations

KalVista Pharmaceuticals Receives Positive Opinion from EMA for Sebetralstat

KalVista's EKTERLY® Receives Approval from UK MHRA

KalVista Pharma released FY2025 Q4 earnings on July 10 (EST), actual revenue USD 0 (forecast USD 32.29 M), actual EPS USD -0.9845 (forecast USD -0.5262)

KalVista Pharma released FY2025 annual earnings on July 10 (EST), actual revenue USD 0 (forecast USD 49.09 M), actual EPS USD -3.6945 (forecast USD -2.7812)

KalVista Pharmaceuticals Reports Expanded Losses for Fiscal 2025

KalVista Pharmaceuticals Receives FDA Approval for EKTERLY®

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

CPRX

KALV

GBTG

Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of KalVista Pharmaceuticals, Global Business Travel Group, Modiv Industrial, and Catalyst Pharmaceuticals. Shareholders are encouraged to discuss their rights and options regarding these transactions, which may not provide fair deals compared to insiders. The firm operates on a contingent fee basis for legal services.

PR Newswire

Modiv Industrial

Catalyst Pharma

Global Business Travel

Global Net Lease

MODIV INDUSTRIAL INC 7.375% CUM RED PERP PFD STOCK SER A

GLOBAL NET LEASE INC 7.25% CUM RED PFRD STOCK SER A USD25

GLOBAL NET LEASE INC 7.375% CUM RED PER PFRD STOCK SER E

GLOBAL NET LEASE INC 7.50% CUM RED PER PFRD STOCK SER D

GLOBAL NET LEASE INC 6.875% CUM RED PER PFD SHS SER B USD25.0

Are KALV, GBTG, MDV, CPRX Obtaining Fair Deals for their Shareholders?

KalVista Pharmaceuticals, Inc. faces increased execution and liquidity risks due to a merger agreement with Chiesi, which restricts its ability to make corporate decisions without consent. This limitation may hinder KalVista's adaptability and growth, especially given its development-stage status. The average stock price target for KALV is $29.17, indicating a potential upside of 9.13%.

Tip Ranks

Merger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity Risks

DRI Healthcare Trust (TSX:DHT) reported a 15% year-over-year growth in total income for Q1 2026, reaching $50.6 million, driven by an 18% increase in royalty income. The adjusted EBITDA margin hit a record 91%. The company executed a $250 million private placement of senior notes, improving its debt profile. Management noted a potential change of control regarding their Ectorly investment due to Calvista Pharmaceuticals' acquisition. DHT.UN aims for continued growth in the royalty market with a balanced portfolio strategy.

benzinga_article

Full Transcript: DRI HEALTHCARE TRUST Q1 2026 Earnings Call

LSTA

SILA

Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties concerning the sales of Sila Realty Trust, KalVista Pharmaceuticals, Thermon Group Holdings, and Lisata Therapeutics. The firm is encouraging shareholders to discuss their rights and options regarding these transactions, which may not provide fair deals compared to insiders. They offer legal assistance on a contingent fee basis, ensuring no upfront costs for shareholders.

Lisata Therapeutics

Sila Realty Trust

Thermon

CECO Environmental

Are SILA, KALV, THR, LSTA Obtaining Fair Deals for their Shareholders?

RMAX

Halper Sadeh LLC is investigating RE/MAX Holdings, Inc. (RMAX), KalVista Pharmaceuticals, Inc. (KALV), and Global Business Travel Group, Inc. (GBTG) for potential violations of federal securities laws and fiduciary duties to shareholders. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders and is seeking increased consideration and disclosures related to the companies' proposed sales. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost.

prnewswire

RE/MAX

Real Brokerage

17:56 ETAre RMAX, KALV, GBTG Obtaining Fair Deals for their Shareholders?

REAX

XOMA

LGND

Halper Sadeh LLC is investigating XOMA, RMAX, and KALV for potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The firm is concerned that insiders may benefit financially from proposed transactions that could limit competing offers. Shareholders are encouraged to contact the firm for their rights and options regarding XOMA's sale to Ligand Pharmaceuticals, RMAX's sale to The Real Brokerage, and KALV's sale to Chiesi Group. Halper Sadeh LLC aims to seek increased consideration and other benefits for shareholders.

XOMA Royalty

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

14:55 ETAre XOMA, RMAX, KALV Obtaining Fair Deals for their Shareholders?

XAIR

PLYX

Short sellers have increased their positions in small-cap healthcare stocks, particularly those under $2 billion market cap, leading to heightened bearish sentiment. Sensei Biotherapeutics tops the list with a short interest of 63.85%, followed by KalVista Pharmaceuticals at 38.35%. Conversely, Beyond Air and Polaryx Therapeutics have minimal short interest at 0.50%. The healthcare sector has underperformed, with the Health Care Select Sector SPDR® Fund declining 6.23% year-to-date, despite the S&P 500's 5.62% rally.

businessinsider

Beyond Air

Polaryx Therapeutics

Most and least shorted healthcare stocks with up to $2B market cap in May

Yesterday's closing, KalVista Pharma's stock price soared 38.62%, closing at $26.67, with an intraday high of $26.76 and a trading volume reaching $1.904 billion, showing several times the average daily level. The MACD daily line formed a bullish signal above the zero axis, combined with such a fierce influx of funds, indicating a typical event-driven violent surge in the technical aspect. Such a huge trading volume means that large-scale funds are actively involved, and market sentiment is in an extremely euphoric state. From the news perspective, the activity level of funds in the biotechnology sector significantly increased yesterday, and KalVista, as a biopharmaceutical company focused on rare diseases such as hereditary angioedema, is likely to have surged due to major clinical progress or collaboration news. The biotechnology sector has frequently seen event-driven market trends recently, and the market is highly sensitive to breakthroughs in innovative drug pipelines. Against the macro backdrop of the Federal Reserve maintaining interest rates, high beta biotechnology stocks often become the focus of speculative funds. From a technical perspective, a nearly 40% increase in a single day indicates that short-term profit-taking has become very substantial, and the stock price has significantly deviated from the short-term moving average system, placing the technical aspect in a severely overbought area. Today, it is crucial to closely monitor whether there are sustained positive news to support the price; if there are no new catalysts, the probability of significant fluctuations or even a rapid pullback during the day is not low. The area around $19 (yesterday's opening range) can be seen as the first reference area for a pullback

Technical Forecast

Pre-market Trend | KalVista Pharma (KALV) surged nearly 40% on 4/29, can the capital frenzy continue?

KalVista Pharma(KALV.US)